Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300763 | 0.86 | NPSR1 (0.39) | NPSR1MAPTKDM4ETDP1LMNA | |
| SCHEMBL1300760 | 0.86 | NPSR1 (0.39) | NPSR1MAPTKDM4ETDP1LMNA | |
| SCHEMBL12108356 | 0.83 | NPSR1 (0.35) | NPSR1MAPTKDM4ETDP1LMNA | |
| SCHEMBL12110921 | 0.76 | MAPT (0.32) | NPSR1MAPTKDM4ETDP1GAA | |
| SCHEMBL16385504 | 0.76 | METTL3 (0.39) | NPSR1MAPTKDM4ETDP1 | |
| SCHEMBL8202831 | 0.74 | NPSR1 (0.44) | NPSR1MAPTKDM4ETDP1LMNA | |
| SCHEMBL16854765 | 0.74 | ALDH1A1 (0.30) | ALDH1A1GAA | |
| SCHEMBL14611574 | 0.74 | ALDH1A1 (0.30) | ALDH1A1GAA | |
| SCHEMBL3289338 | 0.73 | NPSR1 (0.43) | NPSR1MAPTKDM4ETDP1LMNA | |
| SCHEMBL12108199 | 0.72 | NPSR1 (0.36) | NPSR1MAPTKDM4ETDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | NPSR1 4732/4885MAPT 3259/4885KDM4E 656/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | NPSR1 4732/4885MAPT 3259/4885KDM4E 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.